PMID- 21843660
OWN - NLM
STAT- MEDLINE
DCOM- 20120427
LR  - 20111028
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 11
IP  - 11
DP  - 2011 Nov
TI  - Hematologic toxicities associated with intravenous immunoglobulin therapy.
PG  - 1663-7
LID - 10.1016/j.intimp.2011.07.024 [doi]
AB  - Intravenous immunoglobulin (IVIG) is an immunomodulating agent that induces 
      beneficial therapeutic responses in children and adults. IVIG is not only used 
      for prophylaxis and therapy of infections in patients with primary and secondary 
      immunodeficiencies associated with defective antibody production, but also used 
      for treatment of patients with systemic inflammatory disorders, autoimmune 
      diseases, and neuroimmunologic conditions. IVIG is generally considered a safe 
      and efficacious therapeutic modality. However, it is associated with certain 
      adverse effects including hematologic complications such as hemolytic anemia, 
      leukopenia, neutropenia, monocytopenia, disseminated intravascular coagulation, 
      and changes in blood rheology. Venous and arterial thrombotic complications can 
      also occur following treatment with IVIG in high risk patients. It is very 
      important for clinicians to have the knowledge of those adverse events profiles; 
      and this article summarizes hematologic toxicities associated with IVIG therapy 
      reported in the literature; and describes strategies for their identification and 
      management.
CI  - Copyright (c) 2011 Elsevier B.V. All rights reserved.
FAU - Baxley, Allison
AU  - Baxley A
AD  - Department of Pharmacy, University of Nebraska Medical Center, 987680 Nebraska 
      Medical Center, Omaha, NE 68198-7680, United States.
FAU - Akhtari, Mojtaba
AU  - Akhtari M
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20110816
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Hematologic Diseases/blood/*chemically induced/epidemiology/therapy
MH  - Humans
MH  - Immunoglobulins, Intravenous/administration & dosage/*toxicity
MH  - Risk
EDAT- 2011/08/17 06:00
MHDA- 2012/04/28 06:00
CRDT- 2011/08/17 06:00
PHST- 2011/06/20 00:00 [received]
PHST- 2011/07/26 00:00 [revised]
PHST- 2011/07/27 00:00 [accepted]
PHST- 2011/08/17 06:00 [entrez]
PHST- 2011/08/17 06:00 [pubmed]
PHST- 2012/04/28 06:00 [medline]
AID - S1567-5769(11)00301-8 [pii]
AID - 10.1016/j.intimp.2011.07.024 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2011 Nov;11(11):1663-7. doi: 10.1016/j.intimp.2011.07.024. 
      Epub 2011 Aug 16.